Jentadueto is a diabetes medication that may increase a patient’s risk of pancreatitis, pancreatic cancer, bullous pemphigoid, and other severe side effects.
Do I Have a Texas Jentadueto Lawsuit? Collen A. Clark is a true advocate for his clients and is passionate about helping Texans that have been injured or wronged. If you or a loved one was diagnosed with a severe side effect, you should contact our lawyers immediately. You may be entitled to compensation by filing a lawsuit.
Jentadueto Side Effects
- Bile duct disease
- Bullous pemphigoid
- Gallbladder disease
- Pancreatic cancer and pancreatitis
FDA Evaluating Rhabdomyolysis Risk
The FDA is evaluating a potential signals of a serious risk and new safety information linking DPP4 diabetes drugs and rhabdomyolysis. This potentially life-threatening kidney side effect was identified by the FDA Adverse Event Reporting System (FAERS) between April and June 2017.
FDA Safety Warning for Jentadueto and Cancer
What is Jentadueto?
Jentadueto (linagliptin / metformin) is a single-tablet, twice-daily medication to help patients with type-2 diabetes control their blood-sugar levels. It was created by Boehringer Ingelheim and approved by the U.S. Food and Drug Administration (FDA) in January 2012.
What is the problem with Jentadueto?
Jentadueto belongs to a new class of drugs called incretin mimetics, which mimic metabolic hormones (incretins, such as GLP-1) to treat type-2 diabetes. This class of drugs has only been sold since Januvia (sitagliptin) was marketed by Merck in 2006. Since Jentadueto and other incretin mimetic drugs are so new, there is limited information regarding long-term side effects. Unfortunately, there is a growing amount of research linking Jentadueto to a potential risk of pancreatitis, pancreatic cancer, and thyroid cancer.
FDA Investigates Study Linking Jentadueto and Pancreatic Cancer
In 2009, the FDA asked the manufacturers of incretin therapy diabetes drugs to “explore a potential signal of a serious risk of thyroid cancer and pancreatic cancer.” In March 2013, the FDA announced that they were investigating a link between Jentadueto and pancreatic cancer after a concerning study was published in Diabetes.
For the study, researchers autopsied the pancreases of eight patients who had been using a drug in the incretin mimetic class to treat diabetes. These pancreases were compared to pancreases from diabetics who were using other drugs and people who did not have diabetes.
The researchers found that the incretin mimetic group of pancreases were 40% larger, had six times as many beta-cells, and there was alarming evidence of pancreatitis (chronic inflammation) and “eccentric” pre-cancerous cell growth. Furthermore, three pancreases in the incretin mimetic group had pancreatic tumors called adenomas, which normally must be surgically removed because they can become malignant and cause pancreatic cancer.
Jentadueto Class Action
The Clark Firm, LLP is nationally recognized as a class action law firm, but we are not filing a Jentadueto class action. Instead, we are pursuing individual lawsuits against drug-makers for failing to warn about side effects.
As of January 2016, over 750 lawsuits involving pancreatic side effects of incretin therapy diabetes medications were centralized in a Multi-District Litigation (MDL No. 2452) in federal court in California, In Re: Incretin Mimetics Products Liability Litigation.
Need a Jentadueto Lawyer in Texas?
Collen A. Clark is a true advocate for his clients and is passionate about helping Texans that have been injured or wronged.
Collen’s amazing success in the courtroom and well known dedication to his clients has earned him the recognition of his peers as one of The Top Trial Lawyers in Texas.”
The Clark Firm has assembled a team of trial lawyers with more than 100 years experience, participation in over 600 jury trials and $260 million in verdicts and/or settlements. Please use the form below to contact us for a free Texas Jentadueto lawsuit review.